Adverse reactions similar to placebo1

Adverse reactions (ARs) occurring in at least 2% and at a frequency greater than placebo1

Placebo(n=984) UBRELVY 50 mg (n=954) UBRELVY 100 mg (n=485)
Dry Mouth1%<1%2%
Table includes ARs from ACHIEVE I and II.
  • The incidence of adverse reactions in controlled clinical trials was not affected by gender or age2
  • The long-term safety of UBRELVY was further established in 813 patients in a 52-week, open-label trial, with 31,401 doses given3
  • UBRELVY is not a controlled substance, and has not been shown to be habit-forming1
  • No cardiovascular warnings and precautions1

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2019. 2. Data on file. Allergan. 3. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152.